Agomelatine emerges as an option for teen depression

The first paediatric trial of the drug finds it is safe and effective for adolescents but not younger children

Agomelatine in combination with psychosocial counselling could be highly effective for teenagers with major depressive disorder, a landmark study shows.

The melatonin analogue, which is already approved for use in adults, also appears to be well tolerated and is unlikely to result in withdrawal, according to findings in The Lancet Psychiatry.